In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Sonnet BioTherapeutics Holdings (SONN – Research Report), with a price target of $12.00. The company’s shares opened today at $0.37.
According to TipRanks, Nakae is an analyst with an average return of -3.0% and a 33.56% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Arrowhead Pharmaceuticals, and Arbutus Biopharma.
Currently, the analyst consensus on Sonnet BioTherapeutics Holdings is a Moderate Buy with an average price target of $9.35.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.20 and a one-year low of $0.21. Currently, Sonnet BioTherapeutics Holdings has an average volume of 3.9M.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SONN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
Read More on SONN:
